Dr. Edralin named VP of European Chamber of Commerce of the Philippines

• Dr. Edralin is now one of two vice presidents of the ECCP

• Dr. Edralin is the only Filipina and only woman among the 11 current directors of the European-PH chamber.

• Through the ECCP, Roche will advocate for a better healthcare system that benefits all Filipinos regardless of socio-economic status.

MANILA, 06 June 2024 - Dr. Diana M. Edralin, MD, DPCOM, General Manager of Roche (Philippines) Inc., has been elected as Vice President of the European Chamber of Commerce of the Philippines (ECCP) for the term 2024 to 2025, the business group revealed during its recent Annual General Membership Meeting in Taguig City.

Dr. Edralin is now one of two vice presidents of the prestigious chamber, the other being Mr. Roman Menz, CEO of Republic Cement Services Inc. The ECCP also elected Paulo Duarte, managing director of Robert Bosch Inc. in the Philippines, as President for another term.

Dr. Edralin, the GM for the Philippine affiliate of Basel, Switzerland-based Roche since October 2021, was elected to a two-year term on the ECCP Board of Directors in 2023.

She is the only woman among the 11 current directors of the European-PH chamber, which was founded in 1978 and currently boasts of 811 member companies from a vast array of industries.

“I sincerely thank my fellow directors and colleagues in the ECCP for their trust in me to serve alongside Mr. Duarte, our Executive Director Mr. Florian Gottein, and the Chamber’s hardworking and capable team. This is not just another victory for Filipinas, but also for diversity and inclusion, encompassing not only gender but also age and race, among others,” said Dr. Edralin.

“Since our company joined the ECCP in October 2019, we have advocated for a better healthcare system that benefits all Filipinos regardless of socio-economic status, as evidenced by our leadership of the Chamber’s healthcare committee chaired by my colleague, Dr. Ma. Teresa Dioko,” the Roche GM said.

“The ECCP will continue to partner with the Philippine government to strengthen national health systems, as we expressed in an advocacy paper released earlier this year,” Dr. Edralin said.

“We will also help to pass amendments to the Government Procurement Reform Act especially for medicines, institutionalize procurement of healthcare products that are not in the Philippine National Formulary (PNF) or are undergoing Health Technology Assessment (HTA) review, and expand PhilHealth coverage so it can support more patients seeking health services and products, among other healthcare initiatives,” she added.

Dr. Edralin is also on her third term as president of the Pharmaceutical and Healthcare Association of the Philippines (PHAP), and is likewise the first woman leader of the group that represents the research-based pharmaceutical sector in the country. 

Apart from Dr. Edralin, Mr. Duarte, and Mr. Menz, also serving on the ECCP board for the 2024-2025 term are Mr. Jonathan Webster of HSBC Philippines as treasurer; and Albert Perez (Michael Page Philippines), Bernd Schneider (Raffles/Fairmont Makati), Tarang Gupta (Alaska Milk), Jussi Hoikka (Airbus Helicopters Philippines), Jaime Urquijo (Ayala Corporation), Kais Marzouki (Nestle Philippines), and Eric Sajor (Sanofi) as directors. (end)

Note:

MD - Doctor of Medicine

DPCOM - Diplomate, Philippine College of Occupational Medicine

CEO - Chief Executive Officer

About European Chamber of Commerce of the Philippines

The European Chamber of Commerce of the Philippines (ECCP) is a bilateral foreign chamber that promotes European interests in the Philippines and vice versa. As a membership organization with close to 800 members among its ranks and a strong partnership with the government, the ECCP offers a strong business network that holds great potential in translating to tangible business opportunities. The Chamber strives to make its members’ viewpoints heard on economic and business issues, legislative measures, and administrative regulations.

For more information on the ECCP, please visitor email

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the 15th consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. 

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. 

For more information, please visitAll trademarks used or mentioned in this release are protected by law.

Roche (Philippines) Inc.
Unit 801, 8th Floor, The Finance Centre,
9th Ave cor 26th St, Bonifacio Global City,
Taguig City, Metro Manila 1634,
Philippines
Trunk Line:

If you need further information, please consult your Healthcare Provider.

For medical information queries and product quality complaints, please email:

For suspected adverse drug reactions, please report to the Food and Drug Administration (FDA) at aand to the Roche (Philippines) Inc. Patient Safety at

At the first sign of any adverse drug reaction, the patient should seek medical attention immediately.

Contact: Jimbo Owen Gulle, Communications and Corporate Affairs Manager, Roche (Philippines); Phone:/ e-mail: